IDRA Share Price

Open 1.53 Change Price %
High 1.54 1 Day -0.03 -1.99
Low 1.46 1 Week -0.09 -5.73
Close 1.48 1 Month -0.12 -7.50
Volume 671386 1 Year -0.31 -17.32
52 Week High 3.33
52 Week Low 1.19
IDRA Important Levels
Resistance 2 1.55
Resistance 1 1.52
Pivot 1.49
Support 1 1.44
Support 2 1.41
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
APRI 2.86 89.40%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
APRI 2.86 89.40%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
SKBI 0.12 50.00%
UNXL 1.69 34.13%
LIFE 3.25 32.65%
CHCI 2.42 29.41%
GLBS 6.17 27.22%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

IDRA Technical Analysis 5
As on 18th Jan 2017 IDRA Share Price closed @ 1.48 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.79 & Strong Sell for SHORT-TERM with Stoploss of 1.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
IDRA Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
IDRA Other Details
Segment EQ
Market Capital 20456252.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.iderapharma.com
IDRA Address
IDRA
167 Sidney Street
Cambridge, MA 02139
United States
Phone: 617-679-5500
Fax: 617-679-5592
Interactive Technical Analysis Chart Idera Pharmaceuticals, Inc. ( IDRA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Idera Pharmaceuticals, Inc.
IDRA Business Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.